Products for Research Use Only

Lasofoxifene Tartrate

CAT: 0013-GTR19167353-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19167353-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lasofoxifene Tartrate (CP-336156) is a non-steroidal, third-generation selective estrogen receptor modulator (SERM) . It is utilized in research for studying osteoporosis and breast cancer, with applications in both in vitro receptor binding assays and in vivo models for evaluating bone density and mammary tumorigenesis.
CAS Number
190791-29-8
Product Name Alternative
Arthritis, breast cancer, CP 336156, CP336156, CP-336156, Inhibitor, Lasofoxifene, Lasofoxifene Tartrate, EstrogenReceptor, Estrogen Receptor/ERR, Estrogen Receptor, ERR, endocrine resistant, inhibit, oestrogen, oestrogen receptor, osteoporosis, selective oestrogen receptor modulators, tartrate
Field of Research
Metabolism Research, Pharmacology & Drug Discovery
Purity
98.53% (May vary between batches)
Solubility
DMSO:6 mg/mL (10.65 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.77 mM)
Smiles
O[C@@H] ([C@H] (O) C (O) =O) C (O) =O.Oc1ccc2[C@H] ([C@H] (CCc2c1) c1ccccc1) c1ccc (OCCN2CCCC2) cc1
Molecular Formula
C32H37NO8
Molecular Weight
563.64
Storage Conditions
-20°C
Notes
For research use only.

Chemical Information

Lasofoxifene tartrate

Lasofoxifene Tartrate is the tartrate salt form of lasofoxifene, a non-steroidal, naphthalene-derived, third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic and anti-osteoporotic activities. Upon oral administration, lasofoxifene selectively binds to both estrogen receptor alpha (ERalpha; ESR1) and estrogen receptor beta (ERbeta; ESR2) with high affinity and mimics the effects of endogenous estradiol with varying agonist and antagonist effects in ER-expressing tissues. Blockade of ERalpha by lasofoxifene may potentially inhibit estrogen-dependent cancer cell proliferation in ER-expressing cancers. Lasofoxifene may also bind to the certain mutant forms of ERalpha, including the Y537S ESR1 mutant, making it potentially useful in the treatment of tumors that have acquired resistance to other ER-targeting agents.

CAS Number190791-29-8
PubChem CID3081919
IUPAC Name(2S,3S)-2,3-dihydroxybutanedioic acid;(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
Molecular FormulaC32H37NO8
Molecular Weight563.6
Topological Polar Surface Area148
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count9
Rotatable Bond Count9
Heavy Atom Count41
Formal Charge0
Complexity667
SMILES
C1CCN(C1)CCOC2=CC=C(C=C2)[C@H]3[C@H](CCC4=C3C=CC(=C4)O)C5=CC=CC=C5.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O
InChI
InChI=1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1
InChIKey
INEHJXCWEVNEDZ-LUDNRVPPSA-N
Chemical Structure
2D Structure
2D structure of Lasofoxifene tartrate
CAS: 190791-29-8
CID: 3081919
Formula: C32H37NO8
MW: 563.6
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight563.6
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count9
Rotatable Bond Count9
Exact Mass563.25191714
Monoisotopic Mass563.25191714
Topological Polar Surface Area148 Ų
Heavy Atom Count41
Formal Charge0
Complexity667
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count2
Compound Is CanonicalizedYes

Popular Products